Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Angeline Bartholomeusz"'
Autor:
Katherine Merne Griffiths, Sally Soppe, Olan Dolezal, Renae Walsh, Peter Revill, Danni Colledge, Liza Cabuang, Angeline Bartholomeusz, Stewart D. Nuttall, Stephen Locarnini
Publikováno v:
Virology. 411:132-141
The Hepatitis B virus precore protein is processed in the endoplasmic reticulum (ER) into secreted hepatitis B e antigen (HBeAg), which acts as an immune tolerogen to establish chronic infection. Downregulation of secreted HBeAg should improve clinic
Autor:
Henry Lik-Yuen Chan, Kwong-Sak Leung, Kelvin K.F. Tsoi, Eddie Y. T. Ng, Tony Mok, Kin-Hong Lee, Stephen Kwok-Wing Tsui, Thomas Chi Chuen Au, Stephen Locarnini, Chi Hang Tse, Joseph J.Y. Sung, Angeline Bartholomeusz
Publikováno v:
Journal of Virology. 82:3604-3611
We aimed to identify genomic markers in hepatitis B virus (HBV) that are associated with hepatocellular carcinoma (HCC) development by comparing the complete genomic sequences of HBVs among patients with HCC and those without. One hundred patients wi
Autor:
Silvana Gaudieri, Sharon R Lewin, Peter Revill, Christopher P Desmond, Angeline Bartholomeusz
Publikováno v:
Scopus-Elsevier
University of Western Australia
University of Western Australia
BackgroundThe immune response to hepatitis B virus (HBV) is important for both viral control and disease pathogenesis. A detailed understanding of the HBV-specific T-cell responses may potentially lead to novel therapeutic strategies for HBV.MethodsA
Autor:
Belén Ramos, Miriam Romero, Julie Sheldon, Javier García-Samaniego, Stephen Locarnini, Angeline Bartholomeusz, Fabien Zoulim, Pilar Ríos, Vincent Soriano
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 46:279-282
Background: Given the overlap between envelope and polymerase in the hepatitis B virus (HBV) genome, changes in antigenic sites of the HBV surface antigen may occur as a result of selection of drug-resistance mutations. Methods: Serum HBV-DNA was iso
Publikováno v:
Seminars in Liver Disease. 26:162-170
Antiviral drug resistance now poses a major problem for the management of patients with chronic hepatitis B. In theory, resistance may be prevented if a sufficiently potent antiviral drug, or combination of antiviral agents, is used that prevents vir
Autor:
Chloe L. Thio, Gregory J. Dore, Gail V. Matthews, Joe Sasaduesz, Anna Ayres, David A. Cooper, Eric C. Seaberg, Angeline Bartholomeusz, Sharon R Lewin, Stephen Locarnini
Publikováno v:
AIDS. 20:863-870
Background Little is known about the prevalence and pattern of hepatitis B virus (HBV) mutations in HIV/HBV co-infected individuals on long-term lamivudine (3TC) therapy. Methods HBV polymerase/envelope/basal core promoter/pre-core sequences from 81
Publikováno v:
Journal of Hepatology. 44:593-606
Besides interferon, only two drugs—lamivudine and adefovir dipivoxil—are approved as first-line therapy for chronic hepatitis B (CHB) in the EU [1,2]. Each is a nucleoside or nucleotide analogue that acts mainly as a specific inhibitor of the vir
Publikováno v:
Journal of Medical Virology. 78:S52-S55
The hepatitis B virus (HBV) replicates via an error prone viral reverse transcriptase resulting in a large pool of quasispecies with mutations spread throughout the genome. During antiviral drug selection pressure (e.g., lamivudine, adefovir, or ente
Autor:
Angeline Bartholomeusz, Shiv Kumar Sarin, R. C. Guptan, Seyed E. Hasnain, Varsha Thakur, Veena Malhotra, Syed Naqui Kazim
Publikováno v:
Journal of Medical Virology. 76:40-46
Household contacts of HBV-related chronic liver disease patients constitute a high-risk group for acquisition of HBV infection. Some of the HBsAg mutants are associated with liver disease and some are reported to be transmitted vertically. There is l
Autor:
Peter W Angus, Ann W. Walsh, Daniel J. Tenney, Steven Levine, Geoff Thompson, Ronald E. Rose, William Sievert, Angeline Bartholomeusz, Nadia Warner, Linda Discotto, S P Weinheimer, Cheng-Fang Yu, Kevin A. Pokornowski, Mary Jane Plym, Richard J. Colonno, Stephen Locarnini, A Ayres
Publikováno v:
Antimicrobial Agents and Chemotherapy. 48:3498-3507
Entecavir (ETV) exhibits potent antiviral activity in patients chronically infected with wild-type or lamivudine (3TC)-resistant (3TC r ) hepatitis B virus (HBV). Among the patients treated in phase II ETV clinical trials, two patients for whom previ